Stephen V Liu, Associate Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“I remain certain that the microbiome plays a massive role in efficacy (and safety) of immunotherapy. If you missed it, take in this episode of the IASLC (International Association for the Study of Lung Cancer) podcast, Lung Cancer Considered, where I discuss the data with Arielle Elkrief and Bertrand Routy.”
You might be interested in:
AdvanTIG-302: Ociperlimab Plus Tislelizumab Does Not Improve Survival in PD-L1–High NSCLC
